3 Minute Walk Test In Type 2 Diabetes Mellitus
3 Minute Walk Test In Type 2 Diabetes Mellitus
Keywords:
Walk Test, Diabetes Mellitus, Type 2 DMAbstract
Background & Objective: Type 2 Diabetes mellitus(DM) is a chronic disease. It isone of the important causes of increasing morbidity and mortality in India, which is now known as ‘Capital of Diabetes’. It affects all the major systems in the body bringing down the quality of life of the patient. Objective is to assess the Three - minute walk distance in patients and to compare it with the age and gender matched healthy controls. Methodology: A cross- sectional tertiary care Government hospital based study was conducted in forty diagnosed patients of type 2 DM taking oral hypoglycemics, aged between 40-60 years. All the patients were thoroughly interviewed by a well structured questionnaire, which included personal details as well as the history of complications. 3- Minute walk test was conducted, as per the standardized technique in diabetic patients as well as age and gender matched healthy controls. The distance was compared by applying unpaired t test. Results: The mean 3-minute walk distance in patients of type 2 DM was 139.55±54.90 meters as compared to controls which was 200.01± 45.40 meters. The decrease in distance was statistically highly significant (p<0.001). Conclusion: Type 2 Diabetes mellitus affects walking distance of the patient bringing down the quality of life. These findings are useful for targeting the importance of treatment of diabetes, which needs to be addressed with priority to improve the quality of life. [Shah S NJIRM 2016; 7(1):67-70]
References
2. International Diabetes Federation. 2013 (updated on 2014). Diabetes atlas. 6th ed. The global burden. Available from: http://www.idf.org/diabetesatlas/6e/the-globalburden. Accessed 15 Mar, 2015
3. World Health Organization. International Classification of Functioning, Disability and Health. Geneva: WHO; 2001. Available from: http:// www.who.int/icidh. Accessed January 15, 2015.
4. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88–136.
5. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J RespirCrit Care Med. 2002;16:111–17.
6. Mc Gavin CR, Gupta SP, Mc Hardy GJR. Twelve-minutewalking test forassessing disability in chronic bronchitis. Br Med J 1976; 1: 822-23.
7. Butland RJA, Pang J,Gross ER et al.Two, six, and12minutewalking test in respiratory disease. Br Med J 1982; 284: 1607-08.
8. Swinburn CR,Wakefield JM, Jones PW, et al. Performance, ventilation,and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease.Thorax 1985;40: 581-86.
9. Iriberri M, Gáldiz JB, Gorostiza A, Ansola P, Jaca C.Comparison of the distances covered during 3 and 6 min walking test.Respir Med 2002;96:812-16.
10. Cao ZB, Miyatake N, Aoyama T, Higuchi M, Tabata I. Prediction of Maximal Oxygen Uptake From a 3-Minute Walk Based on Gender, Age, and Body Composition. Journal of Physical Activity and Health 2013; 10: 280-87
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28:37–42.
12. Latiri I, Elbey R, Hcini K, Zaoui A, Charfeddine B, Maarouf MR, and Tabka Z. Six-minute walk test innon-insulin-dependent diabetes mellitus patients living in Northwest Africa. Diabetes MetabSyndrbes. 2012;5:227-45.
13. Pan AM1, Stiell IG, Clement CM, Acheson J, Aaron SD.Feasibility of a structured 3-minute walk test as a clinical decision tool for patients presenting to the emergency department with acute dyspnoea.Emerg Med J. 2009;26:278-82.
14. Shah SH, Sonawane PP, Nahar PS, Buge KH, Vaidya SM. Are we ignoring diabetic disability?A cross sectional study of diabetic myopathy. Indian Journal of Medical Sciences 2011; 65:186-92
15. Ijzerman TH, Schaper NC, Melai T, Meijer K, Willems PJ, Savelberg HH. Lower extremity muscle strength is reduced in people with type 2 diabetes with and without poly neuropathy and is associated with impaired mobility and reduced quality of life. Diabetes Res ClinPract 2012;95:345-51
16. Sun Z, Liu L, Liu N, Liu Y. Muscular response and adaptation to diabetes mellitus. Front Biosci. 2008;13:4765–94.
17. Llovera M, GarcÃa-MartÃnez C, Agell N, López-Soriano FJ, Argilés JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. BiochemBiophys Res Commun. 1997;13:238–41.
18. Kusminski CM, Shetty S, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. Apoptosis. 2009;14:1484–95.
19. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–12.
20. Mercier J. Peripheral muscles and metabolic diseases. Rev Mal Respir. 2001;18(Suppl 2):22–24.
21. Moulias S. Myopathies of the elderly. Rev Rhum. 2004;71:510–14.
22. Simoneau J, Kelley D. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol. 1997;83:166–71.
23. Marin P, Anderson B, Krotkiewski M, Björntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care. 1994;17:382–86.
24. Rodbard H. AACE Diabetes mellitus clinical practice guidelines task force. EndocrPract. 2007;13:1–31.
25. Ahmann A. Guidelines and performance measures for diabetes. Am J Manag Care. 2007;13:41–46.
